

## Information for Vermont Prescribers of Prescription Drugs (Short Form)

### NURTEC® ODT (rimegepant) orally disintegrating tablets (ODT), for sublingual or oral use

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.
- The prices listed below are Wholesale Acquisition Costs ("WAC") plus 20% as established and made available to the public by a third party publisher or as calculated from data made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about the WAC of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost of effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

**Price Comparison:** Marketed product and lowest dosage of other products in same therapeutic class.\*

#### Marketed Product:

NURTEC ODT 75 MG TABLET	\$149.85
-------------------------	----------

#### Other Products

QULIPTA 10 MG TABLET	\$43.70
UBRELVY 50 MG TABLET	\$123.98

\*Prices shown are for the lowest dosage of each product. Prices for multi-source products have been averaged. Multiple forms of the same product (e.g. tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included.

For additional price comparison information, see:  
<http://www.pfizer.com/vtprescribers>

Pfizer does not set or determine the WACs listed on this form or published by third party publisher. WACs published by third party publisher may not reflect actual prices charged by wholesalers or average of such prices.

Data as of: 02-Apr-2024